Product information and disease descriptionPlace of product in therapyApproaches to treatment
Current treatment options and standard of care
208 evidence topics · 67 sources
Hovilpri (pritelivir)
Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults
- Manufacturer
- Asahi Kasei Therapeutics
- Regulatory submission
- NDA submitted February 2026 and approved October 2026
- Last updated